A major contributor to this article appears to have a close connection with its subject. (December 2021) |
Sintilimab, sold under the brand Tyvyt among others, is a medication used to treat Hodgkin's disease,[2] and has been approved in China.[3]
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Clinical data | |
| Other names | Anti-PD-1 monoclonal antibody IBI308[1] |
| Identifiers | |
| CAS Number | |
| UNII | |
| KEGG | |
It is a fully human IgG4 monoclonal antibody[4] that binds to programmed cell death protein 1.[5]
It was jointly developed by Innovent Biologics[6] and Eli Lilly.[7]
Medical uses
editSintilimab is medication that is indicated for the treatment of relapsed or refractory classical Hodgkin's lymphoma[8] after failure of at least second-line systemic chemotherapy.[5]
Side effects
editCommon side effects include fever, thyroid dysfunction, elevation of liver enzymes, and lung inflammation.[9]
Research
editCurrently, more than 20 clinical trials are ongoing to evaluate the anti-tumor effect of sintilimab injection, either as monotherapy or in combination with other agents, on a variety of solid tumors.[10] In January 2019, the result of the registration trial of sintilimab in people with refractory or relapsed classical Hodgkin's lymphoma was published.[8]
References
edit- ^ "anti-PD-1 monoclonal antibody IBI308". NCI Drug Dictionary. National Cancer Institute. 2011-02-02.
- ^ "Antibody Drug Conjugates Market Growth Forecast Analysis by Manufacturers, Regions, Type and Application to 2026". Reuters. October 24, 2018.
- ^ "NMPA Approves Tyvyt For Hodgkin's lymphoma Read". Asian Scientist Magazine. January 9, 2019.
- ^ Ying K, Xu N, Jiang H, Liu Y, Zhou H, Wang S (2018). "OA08 Efficacy and Safety of Sintilimab Combined with 1st Line Chemotherapy in Advanced Squamous Cell Non-small Cell Lung Cancer". Journal of Thoracic Oncology. 13 (12): S1047. doi:10.1016/j.jtho.2018.10.018. Retrieved Dec 1, 2018.
- ^ a b Hoy SM (February 2019). "Sintilimab: First Global Approval". Drugs. 79 (3): 341–346. doi:10.1007/s40265-019-1066-z. PMID 30742278. S2CID 59945274.341-346&rft.date=2019-02&rft_id=https://api.semanticscholar.org/CorpusID:59945274#id-name=S2CID&rft_id=info:pmid/30742278&rft_id=info:doi/10.1007/s40265-019-1066-z&rft.aulast=Hoy&rft.aufirst=SM&rfr_id=info:sid/en.wikipedia.org:Sintilimab" class="Z3988">
- ^ "Chi-Med Announces Amendment to the 2013 License & Collaboration Agreement on Fruquintinib with Eli Lilly and Company". SEC.gov. December 20, 2018.
- ^ "Sintilimab - Eli Lilly/Innovent Biologics". Adis Insight. Springer Nature Switzerland AG. 28 March 2019.
- ^ a b Ansell SM (January 2019). "Sintilimab: another effective immune checkpoint inhibitor in classical Hodgkin lymphoma". The Lancet. Haematology. 6 (1): e2 – e3. doi:10.1016/S2352-3026(18)30210-2. PMID 30612711. S2CID 58561198.e2 - e3&rft.date=2019-01&rft_id=https://api.semanticscholar.org/CorpusID:58561198#id-name=S2CID&rft_id=info:pmid/30612711&rft_id=info:doi/10.1016/S2352-3026(18)30210-2&rft.aulast=Ansell&rft.aufirst=SM&rfr_id=info:sid/en.wikipedia.org:Sintilimab" class="Z3988">
- ^ A first-in-human phase 1a trial of sintilimab (IBI308). 2018 ASCO Annual Meeting. American Society of Clinical Oncology. 12 October 2019.
- ^ Innovent Biologics, Inc. "Innovent Organized a Forum Discussing the Pending Launch of its Anti PD-1 Tyvyt® (Sintilimab injection)". PR NewsWire (Press release). Retrieved Feb 22, 2019.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |